|
Cognition Disorders
|
0.320 |
Biomarker
|
group |
BEFREE |
The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice.
|
21544067 |
2011 |
|
Cognition Disorders
|
0.320 |
Biomarker
|
group |
CTD_human |
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.
|
17581637 |
2007 |
|
Cognition Disorders
|
0.320 |
AlteredExpression
|
group |
BEFREE |
The fine tuning of CDK5R1 expression by 3'-UTR may have a role in central nervous system development and functioning, with potential implications in neurodegenerative and cognitive disorders.
|
18053171 |
2007 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Hence, heterozygous p35 knockout mice model both cognitive endophenotypes and molecular changes reminiscent of schizophrenia.
|
21772061 |
2011 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Hence, heterozygous p35 knockout mice model both cognitive endophenotypes and molecular changes reminiscent of schizophrenia.
|
21772061 |
2011 |
|
Brain Diseases
|
0.310 |
Biomarker
|
group |
BEFREE |
Malfunctioning of cyclin-dependent kinase 5 (CDK5) through aberrant proteolytic cleavage of its neuronal activators p35 and p39 is involved in neurodegeneration in Alzheimer's disease (AD) and other neurodegenerative brain diseases.
|
15917097 |
2005 |
|
Brain Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling.
|
15665076 |
2005 |
|
Nerve Degeneration
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Furthermore, injection of SIRT1 lentivirus in the hippocampus of p25 transgenic mice conferred significant protection against neurodegeneration.
|
17581637 |
2007 |
|
Encephalopathies
|
0.300 |
Biomarker
|
group |
CTD_human |
Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling.
|
15665076 |
2005 |
|
Hypoxia-Ischemia, Brain
|
0.200 |
Therapeutic
|
disease |
RGD |
The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
|
25665755 |
2015 |
|
Hypothyroidism
|
0.200 |
Biomarker
|
disease |
RGD |
Developmental hypothyroidism induced by iodine deficiency and PTU treatment could delay the maturation of newborn granule neurons in dentate gyrus, and this deficit may be attributed to the downregulation of p35.
|
22987596 |
2014 |
|
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
MGD |
TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory.
|
23064382 |
2012 |
|
Trigeminal Neuralgia
|
0.200 |
Biomarker
|
disease |
RGD |
[Expression and activity of Cdk5/p35 in a rat model of trigeminal neuropathic pain].
|
21161138 |
2010 |
|
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
MGD |
Attention-deficit/hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35.
|
20832057 |
2010 |
|
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
MGD |
Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality.
|
9010203 |
1997 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may contribute to Alzheimer's disease.
|
31068217 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An increased level of the p25 activator of CDK5 kinase was found in AD-PHF-injected 5xFAD mice.
|
30599077 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate sex differences in the effects of p35 reduction on biochemical pathways relevant to the modulation of Aβ plaque deposition and confirm the importance of examining both sexes in preclinical AD research.
|
31421203 |
2019 |
|
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Deregulation of Cdk5 is a hallmark in neurodegenerative diseases and its complex with p25 forms Cdk5/p25, thereby causes severe neuropathological insults.
|
31073393 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
An inducible mouse model of p25 accumulation (the CK-p25 mouse) that displays key pathological hallmarks of Alzheimer disease (AD) is used as a gold-standard to test the proposed algorithm by providing a conditional control of rapid neurodegeneration.
|
29723637 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All ADC values correlated inversely with tumor cellularity with the strongest correlation between P10, P25 and mean cell count (-0.558).
|
29782920 |
2018 |
|
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Deregulation of cyclin-dependent kinase 5 (Cdk5) is believed to play an important role in neurodegenerative diseases including PD. p25 is a cleavage peptide of p35, a physiologic activator of Cdk5. p25 combines to Cdk5 and leads to the hyperactivity of Cdk5, which in turn hyperphosphorylates downstream substrates and leads to neuroinflammation and apoptosis of neurons.
|
29910724 |
2018 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the downregulation of the miR-15/107 family might have a role in the pathogenesis of AD by increasing the levels of CDK5R1/p35 and consequently enhancing CDK5 activity.
|
27343180 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulation of Cyclin-dependent kinase 5 (Cdk5) activity by production of its hyperactivator p25 is involved in the formation of tau and amyloid pathology reminiscent of Alzheimer's disease (AD).
|
29036814 |
2017 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin-dependent kinase 5 (Cdk5), which binds to and is activated by p35, phosphorylates multiple substrates and plays an essential role in the development and function of the CNS; however, proteolytic production of p25 from p35 under stress conditions leads to the inappropriate activation of Cdk5 and contributes to hyperphosphorylation of τ and other substrates that are related to the pathogenesis of Alzheimer's disease.
|
28420695 |
2017 |